XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.

Rentokil flags debugged trend towards mega buyouts



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>BREAKINGVIEWS-Rentokil flags debugged trend towards mega buyouts</title></head><body>

The author is a Reuters Breakingviews columnist. The opinions expressed are her own. Updates to add graphic.

By Karen Kwok

LONDON, July 22 (Reuters Breakingviews) -A potential takeover of London-listed rat-catcher Rentokil RTO.L is a sign that mega buyouts are getting debugged. Former BT BT.L boss Philip Jansen is talking to private equity groups about taking the $17 billion company private, says the Sunday Times. Similar-sized deals look increasingly possible given easier debt markets. The challenge is persuading shareholders to sell.

Rentokil is not the only potential large buyout now on the cards. Unilever ULVR.L is talking to private equity firms to sell its ice cream business, worth a reported 15 billion pounds, Bloomberg says. Pharma giant Sanofi’s SASY.PA $20 billion spinoff of its consumer drugs business has attracted interest from Bain Capital and Cinven.

It’s certainly getting easier to finance big deals. Central banks are cutting rates, which reduces borrowing costs. The extra return investors demand to hold risky junk-rated bonds over safe government ones has fallen by around 1 percentage point in Europe over the last year, to 3.3 percentage points, per LSEG data. Issuance of European collateralised loan obligations, a key source of financing for buyout debt, is surging, with new CLO volumes reaching 24 billion euros in the first six months of the year, according to PitchBook LCD, more than double the rate of last year.

And Rentokil would be a juicy catch. A messy integration following the 2022 takeover of rival Terminix has left the group with a pile of debt and lacklustre growth. With a 30% premium to Friday’s undistributed price, the company would be worth 17.7 billion pounds including net debt, just 14 times the EBITDA that analysts expect it to generate this year, Visible Alpha data shows. U.S. peer Rollins ROL.N is trading at 31 times.

The buyers wouldn’t need to work too hard to get a good return. Analysts expect Rentokil’s EBITDA to grow by roughly 5% annually in the next five years, according to Visible Alpha. Assume the new owners can boost that to 7.5%, closing around half the gap with Rollins, and then re-list Rentokil at 20 times EBITDA, its peak multiple from 2020. That would deliver an internal rate of return of over 20%, according to Breakingviews calculations, which assume debt of 6 times EBITDA and interest costs of 8%.

Jansen and his backers would need to stump up a lot of money; even with that level of borrowing the equity cheque would likely exceed 10 billion pounds. The bigger challenge would be persuading Rentokil’s shareholders to sell. After all, they could capture a lot more upside if Chief Executive Andy Ransom can turn the business around. If Rentokil was valued in line with its 2020 peak multiple of 20 times forward EBITDA, its market capitalisation would reach 22 billion pounds, over 70% above the current equity value, according to Breakingviews calculations. With ever bigger mousetraps, private equity will have to dangle a lot of cheese.

Follow @karenkkwok on X


CONTEXT NEWS

Former BT CEO Philip Jansen is studying a buyout of Rentokil, the UK-listed rat-catching firm, the Sunday Times newspaper reported on July 21.

A buyout could value Rentokil at 15 billion pounds, assuming a standard takeover premium of 30%, the Times said, adding that Jansen has worked in the past with Bain Capital, on the buyout of payments group Worldpay.

Rentokil shares were up around 10% as of 0820 GMT.


Graphic: Rentokil traded at its peak in July 2020 https://reut.rs/3SkFjQu


Editing by Neil Unmack and Aditya Srivastav

</body></html>

면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.